References
  1. P. Zhou et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
  2. Chen et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 395, 507–513 (2020).
  3. World Health Organization, Coronavirus disease (COVID-19) Pandemic. https://www. who.int/emergencies/diseases/novel-coronavirus-2019.
  4. H. Lu. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci. Trends 14, 69
  5. Casadevall A, and Pirofski LA. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 2003;24(9):474-8. 4.
  6. Casadevall A, and Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy.Antimicrob Agents Chemother. 1994;38(8):1695-702.
  7. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343. 10.1371/journal.pmed.0030343
  8. Yaseen M. Arabi et al. Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection . Saudi Arabia Emerg Infect Dis. 2016 Sep; 22(9): 1554–1561. doi: 10.3201/eid2209.151164
  9. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, et al.Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144:464–73. 10.1378/chest.12-2907
  10. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al.Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52:447–56. 10.1093/cid/ciq106
  11. Van Erp EA, Luytjes W, Ferwerda G, and van Kasteren PB.Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease . Front Immunol. 2019;10:548.
  12. Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS, Wec AZ, et al.A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. Cell Host Microbe. 2018;24(2):221-33.e5. 15.
  13. Zhang JS, Chen JT, Liu YX, Zhang ZS, Gao H, Liu Y, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol. 2005;77(2):147-50. 16.
  14. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44-6.
  15. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv. 2020:2020.03.16.20036145. 23
  16. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.JAMA. 2020. 22.
  17. Ye M et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.J Med Virol. 2020 Apr 15. doi: 10.1002/jmv.25882.
  18. Rajendran K et al. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review.
  19. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv. 2020:2020.03.16.20036145.
  20. Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis. 2002;8(8):833-41.
  21. FDA. Electronic Code of Federal Regulations: 630.30 Donation suitability requirements. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=630.3. Updated March 17, 2020 Accessed March 19, 2020
  22. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens . JAMA. 2020.